SEC Form 4 · accession 0001764157-26-000004
Allogene Therapeutics, Inc. · ALLO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Elizabeth A. Barrett
Director
Period of report
Jun 18, 2026
Accepted (ET)
Jun 23, 2026 · 4:26 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001737287
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitF1 | — | Jun 18, 2026 | A | 95,400 | A | — | — | Common Stock | 95,400 | 95,400 | D |
Explanation of responses
- F1Represents an award of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Company Common Stock. The RSUs will vest in two successive equal semi-annual installments over the one-year period measured from the date of grant, subject to continued service through the vesting date. The reporting person has elected to defer the receipt of Common Stock upon the vesting of their RSUs pursuant to the Company's Non-Employee Director Compensation Policy until earlier of (i) 30 days following separation from continuous service with the company and (ii) a change in control of the Company.